Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRL1 | P41146 | 2/20 | 0.37 |
| ▸ | CYP17A1 | P05093 | 12/20 | 0.36 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.36 |
| ▸ | AXL | P30530 | 1/20 | 0.34 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.34 |
| ▸ | HIPK2 | Q9H2X6 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28509018 | 0.94 | OPRL1 (0.35) | OPRL1CYP17A1RPS6KA3AXLHIPK2 | |
| SCHEMBL13735438 | 0.92 | CYP11B2 (0.44) | OPRL1CYP17A1RPS6KA3CYP11B2 | |
| SCHEMBL7259298 | 0.90 | CYP11B2 (0.47) | OPRL1CYP17A1CYP11B2 | |
| SCHEMBL29079894 | 0.83 | CHRNB2 (0.36) | OPRL1CYP17A1AXLCYP11B2HIPK2 | |
| SCHEMBL743476 | 0.76 | RPS6KA3 (0.33) | OPRL1RPS6KA3AXL | |
| SCHEMBL745178 | 0.75 | AXL (0.32) | AXL | |
| SCHEMBL29517316 | 0.74 | AOC1 (0.42) | OPRL1CYP17A1 | |
| SCHEMBL793573 | 0.74 | OPRL1 (0.37) | OPRL1CYP17A1RPS6KA3CYP11B2HIPK2 | |
| SCHEMBL29410681 | 0.74 | RPS6KA3 (0.42) | OPRL1CYP17A1RPS6KA3HIPK2 | |
| SCHEMBL16132536 | 0.74 | OPRL1 (0.57) | OPRL1CYP17A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260027113-A1 | PHTHALAZINONE BASED MODULATORS FOR THE TREATMENT OF DISEASE | SOLEY THERAPEUTICS INC (US) | 2026-01-29 | — | — | US | disclosed |
| US-12465603-B2 | Phthalazinone based modulators for the treatment of disease | SOLEY THERAPEUTICS, INC. (US) | 2025-11-11 | — | — | US | disclosed |
| EP-4619387-A1 | PHTHALAZINONE BASED MODULATORS FOR THE TREATMENT OF DISEASE | Soley Therapeutics, Inc. (US) | 2025-09-24 | — | — | EP | disclosed |
| US-20250215029-A1 | STAT MODULATORS AND USES THEREOF | RECLUDIX PHARMA, INC. | 2025-07-03 | — | — | US | disclosed |
| US-20250136570-A1 | HDAC INHIBITORS AND THERAPEUTIC USE THEREOF | TANGO THERAPEUTICS, INC. | 2025-05-01 | — | — | US | disclosed |
| EP-4463459-A1 | STAT MODULATORS AND USES THEREOF | Recludix Pharma, Inc. (US) | 2024-11-20 | — | — | EP | disclosed |
| US-20240374589-A1 | PHTHALAZINONE BASED MODULATORS FOR THE TREATMENT OF DISEASE | SOLEY THERAPEUTICS, INC. | 2024-11-14 | — | — | US | disclosed |
| CN-118804917-A | STAT modulators and uses thereof | 瑞克鲁迪克斯制药股份有限公司 | 2024-10-18 | — | — | CN | disclosed |
| EP-4441033-A1 | NOVEL HDAC INHIBITORS AND THERAPEUTIC USE THEREOF | Tango Therapeutics, Inc. (US) | 2024-10-09 | — | — | EP | disclosed |
| CN-118715206-A | Novel HDAC inhibitors and therapeutic uses thereof | 探戈医药股份有限公司 | 2024-09-27 | — | — | CN | disclosed |
| US-20140148453-A1 | SULFONAMIDE COMPOUNDS USEFUL AS CYP17 INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2014-05-29 | — | — | US | disclosed |
| EP-2701512-A1 | ALDOSTERONE SYNTHASE INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2014-03-05 | — | — | EP | disclosed |
| US-20140045819-A1 | ALDOSTERONE SYNTHASE INHIBITORS | ELEXOPHARM GMBH (DE) | 2014-02-13 | — | — | US | disclosed |
| US-20140045819-A1 | ALDOSTERONE SYNTHASE INHIBITORS | ELEXOPHARM GMBH (DE) | 2014-02-13 | — | — | US | disclosed |
| US-20140045819-A1 | ALDOSTERONE SYNTHASE INHIBITORS | ELEXOPHARM GMBH (DE) | 2014-02-13 | — | — | US | disclosed |
| EP-2598481-A1 | SULFONAMIDE COMPOUNDS USEFUL AS CYP17 INHIBITORS | Bristol-Myers Squibb Company (US) | 2013-06-05 | — | — | EP | disclosed |
| WO-2012148808-A1 | ALDOSTERONE SYNTHASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2012-11-01 | — | — | WO | disclosed |
| WO-2012015723-A1 | SULFONAMIDE COMPOUNDS USEFUL AS CYP17 INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-02-02 | — | — | WO | disclosed |
| WO-2012015723-A1 | SULFONAMIDE COMPOUNDS USEFUL AS CYP17 INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-02-02 | — | — | WO | disclosed |
| WO-2003027105-A1 | SUBSTITUTED 3-PYRIDYL THIOPHENES AS C17,20 LYASE INHIBITORS | BAYER PHARMACEUTICALS CORPORATION (US) | 2003-04-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12465603-B2 | Phthalazinone based modulators for the treatment of disease | MKI67, BCL2, CCAR2 | OPRL1 4308/4885CYP17A1 474/4885RPS6KA3 585/4885 |
| US-20260027113-A1 | PHTHALAZINONE BASED MODULATORS FOR THE TREATMENT OF DISEASE | NCOR1, NOP56, NCOR2 | OPRL1 1032/4885CYP17A1 720/4885RPS6KA3 363/4885 |
| US-20250215029-A1 | STAT MODULATORS AND USES THEREOF | STAT6, STAT3, STAT5A | OPRL1 4189/4885CYP17A1 2155/4885RPS6KA3 359/4885 |
| US-20140148453-A1 | SULFONAMIDE COMPOUNDS USEFUL AS CYP17 INHIBITORS | SULT1A1, SULT2A1, SULT1E1 | OPRL1 987/4885CYP17A1 28/4885RPS6KA3 1166/4885 |
| US-20250136570-A1 | HDAC INHIBITORS AND THERAPEUTIC USE THEREOF | HDAC1, HDAC7, HDAC5 | OPRL1 4714/4885CYP17A1 657/4885RPS6KA3 860/4885 |
| US-20240374589-A1 | PHTHALAZINONE BASED MODULATORS FOR THE TREATMENT OF DISEASE | MKI67, HDAC6, BCL2 | OPRL1 4490/4885CYP17A1 518/4885RPS6KA3 530/4885 |
| US-20140045819-A1 | ALDOSTERONE SYNTHASE INHIBITORS | CYP21A2, CYP17A1, HSD11B1 | OPRL1 3433/4885CYP17A1 2/4885RPS6KA3 1209/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.